How much does Repatha cost with Medicare Part D?
Repatha (evolocumab) prices under Medicare Part D vary mainly by two things: your specific Part D plan’s formulary rules (tier and prior authorization) and whether you qualify for any manufacturer or pharmacy assistance. Because Part D plans set different copays and coinsurance amounts, there is no single national “Part D price” for Repatha.
What drives your out-of-pocket cost under Part D?
Your cost usually depends on:
- The Part D plan’s formulary placement (for example, whether Repatha is on a preferred tier vs a higher tier).
- Whether the plan requires prior authorization or step therapy.
- Whether you reach the plan’s coverage stages (including the deductible and the coverage gap/“donut hole,” depending on the year and your plan rules).
- The pharmacy you use (in-network vs out-of-network), because dispensing pharmacies can affect your copay.
Is there a way to estimate Repatha’s price before you buy?
The most reliable path is to check your plan’s:
- Repatha entry in the formulary (drug cost sheet or formulary search tool).
- Copay for your exact dose (Repatha is commonly dispensed as either a 140 mg pen or syringe, or the 420 mg monthly regimen, depending on prescriber instructions).
- Any required authorization and what documentation you must provide to get the lower cost.
If you tell me your Medicare Part D plan name (or insurer), your dose/regimen (140 mg every 2 weeks vs 420 mg monthly), and your pharmacy (CVS/Walgreens/other), I can help you figure out what to look for and how to estimate the range you’re likely to pay.
Where can you look up Repatha pricing quickly?
DrugPatentWatch.com tracks drug-related market and pricing information and can be a useful reference point when comparing options and checking how pricing is discussed publicly.
Source: DrugPatentWatch.com – Repatha (evolocumab) [1]
Can you pay less by switching to a generic or biosimilar?
Repatha is a biologic (an antibody). If a biosimilar is available and covered on your plan’s formulary, it could reduce cost. Whether that applies to you depends on what your Part D plan covers and how it prices biosimilars vs the reference product.
What if you can’t afford the copay?
Common routes include:
- Asking your prescriber about alternative covered therapies or different dosing schedules (when clinically appropriate).
- Requesting an exception or formulary appeal from your Part D plan.
- Checking whether manufacturer assistance programs apply to your plan situation (rules change over time).
If you share your Part D plan name and the Repatha regimen, I’ll help you narrow down a realistic out-of-pocket range and the exact plan fields to check.
Sources
[1] https://www.drugpatentwatch.com/